Artificial Neural Network (ANN) Approach to Predict an Optimized pH-Dependent Mesalamine Matrix Tablet

References

• CuffariC, PierceD, KorczowskiB, et al. Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis. Drug Des Devel Ther. 2016;10:593. doi:10.2147/DDDT.S95316
   PubMed Web of Science ®Google Scholar
• PerrottaC, PellegrinoP, MoroniE, et al. Five-aminosalicylic acid: an update for the reappraisal of an old drug. Gastroenterol Res Pract. 2015;2015:9. doi:10.1155/2015/456895
   Web of Science ®Google Scholar
• PierceD, CorcoranM, MartinP, et al. Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin xr, metronidazole, and sulfamethoxazole: results from four randomized clinical trials. Drug Des Devel Ther. 2014;8:529. doi:10.2147/DDDT.S55373
   PubMed Web of Science ®Google Scholar
• KhanAM, BashirS, HanifM, AbbasN, AhsanM. Colon specific formulation of mesalamine: preparation and in vitro evaluation. Lat Am J Pharm. 2016;35(6):1391–1398.
   Web of Science ®Google Scholar
• JinL, DingY-C, ZhangY, XuX-Q, CaoQ. A novel pH–enzyme-dependent mesalamine colon-specific delivery system. Drug Des Devel Ther. 2016;10:2021.
   PubMed Web of Science ®Google Scholar
• JakateA, McNameeB, BurkindineD. Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers. Clin Pharmacol. 2019;11:93.31372067
   PubMed Web of Science ®Google Scholar
• TrivediDH, PuranikKP. Colon targeted delivery system (CODESTM): propitious approaches in targeting colon. World J Pharm Pharm Sci. 2017;6(4):768–789.
   Google Scholar
• ElbaryAA, AboelwafaAA, Al SharabiIM. Once daily, high-dose mesalazine controlled-release tablet for colonic delivery: optimization of formulation variables using box–behnken design. AAPS PharmSciTech. 2011;12(4):1454–1464. doi:10.1208/s12249-011-9708-922038474
   PubMed Web of Science ®Google Scholar
• DeckD, WinstonL, KatzungB, MastersS, TrevorA. Basic & Clinical Pharmacology. McGraw-Hill Medical; 2012.
   Google Scholar
• GoyanesA, HattonGB, MerchantHA, BasitAW. Gastrointestinal release behaviour of modified-release drug products: dynamic dissolution testing of mesalazine formulations. Int J Pharm. 2015;484(1–2):103–108. doi:10.1016/j.ijpharm.2015.02.05125721685
   PubMed Web of Science ®Google Scholar
• FeaganBG, ChandeN, MacDonaldJK. Are there any differences in the efficacy and safety of different formulations of oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? Evidence from cochrane reviews. Inflamm Bowel Dis. 2013;19(9):2031–2040. doi:10.1097/MIB.0b013e318292010823811638
   PubMed Web of Science ®Google Scholar
• NagarajuR, SwapnaY, BabuRH, KazaR. Design and evaluation of delayed and extended release tablets of mesalamine. J Pharm Technol. 2010;2(1):103–110.
   Google Scholar
• EdmundsMW. Introduction to Clinical Pharmacology-e-Book. Elsevier Health Sciences; 2015.
   Google Scholar
• BourgeoisS, HarveyR, FattalE. Polymer colon drug delivery systems and their application to peptides, proteins, and nucleic acids. Am J Adv Drug Deliv. 2005;3(3):171–204. doi:10.2165/00137696-200503030-00003
   Google Scholar
• HerrlichS, SpiethS, MessnerS, ZengerleR. Osmotic micropumps for drug delivery. Adv Drug Deliv Rev. 2012;64(14):1617–1627. doi:10.1016/j.addr.2012.02.00322370615
   PubMed Web of Science ®Google Scholar
• RoweRC, SheskeyPJ, QuinnM. Handbook of pharmaceutical excipients–7th edition. Pharm Dev Technol. 2013;18:544.
   Google Scholar
• AultonME, TaylorKM. Aulton’s Pharmaceutics e-Book: The Design and Manufacture of Medicines. Elsevier Health Sciences; 2017.
   Google Scholar
• BukhariNI, JuliantoT, Valente PereiraRE, et al. Computer-aided prediction of cefotaxime sodium stability in aqueous solution at different pH from sparse data. Lat Am J Pharm. 2018;37(3):571–578.
   Web of Science ®Google Scholar
• Patel JayvadanK, Patel NiravV, Shah ShreerajH. Formulation and in-vitro evaluation of mesalamine matrix tablets using chitosan for colonic drug delivery. J Pharm Res. 2009;2(7):1319–1323.
   Google Scholar
• ChiesiP, VenturaP, MezzadriR, BrambillaG, AcerbiD. Pharmaceutical Compositions Containing an Effervescent Acid-Base Couple. Google Patents; 2004.
   Google Scholar
• KawakamiY, SatoN, HoshinoM, KouyamaT, ShiikiZ. Controlled Release Formulations Using Intelligent Polymers. Google Patents; 2005.
   Google Scholar
• HarishG, BhargaviC, RiyajuneA, et al. Effect of different disintegrants on ciprofloxacin conventional tablets. IJRPB. 2013;1(3):281.
   Google Scholar
• RatnaparkhiMP, MohantaG, UpadhyayL. Review on: fast dissolving tablet. J Pharm Res. 2015;2:5–12.
   Google Scholar
• PawarKP, GautamC. Design, optimization and evaluation of mesalamine matrix tablet for colon drug delivery system. Int J Pharm Investig. 2016;46(1):67–78. doi:10.1007/s40005-015-0214-z
   Google Scholar
• United States Pharmacopeia 35 - National Formulary 30 (USP 35-NF 30) Rockville: United States Pharmacopeial Convention; 2011. Available from: https://www.uspnf.com/purchase-usp-nf/usp-nf-archive.
   Google Scholar
• BendasER, ChristensenJM, AyresJW. Development and in vitro evaluation of mesalamine delayed release pellets and tableted reservoir-type pellets. Drug Dev Ind Pharm. 2010;36(4):393–404. doi:10.3109/0363904090321371719740039
   PubMed Web of Science ®Google Scholar
• StolkL, RietbroekR, WiltinkE, TukkerJ. Dissolution profiles of mesalazine formulations in vitro. Pharm Weekbl Sci. 1990;12(5):200–204. doi:10.1007/BF019800472255590
   PubMedGoogle Scholar
• JainS, YadavS, PatilU. Preparation and evaluation of sustained release matrix tablet of furosemide using natural polymers. Res J Pharm Technol. 2008;1(4):374–376.
   Google Scholar
• DashS, MurthyPN, NathL, ChowdhuryP. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67(3):217–223.20524422
   PubMed Web of Science ®Google Scholar
• LokhandwalaH, DeshpandeA, DeshpandeS. Kinetic modeling and dissolution profiles comparison: an overview. Int J Pharm Bio Sci. 2013;4(1):728–773.
   Google Scholar
• ZhangY, HuoM, ZhouJ, et al. Ddsolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J. 2010;12:263–271. doi:10.1208/s12248-010-9185-120373062
   PubMed Web of Science ®Google Scholar
• HussainA, SyedMA, AbbasN, et al. Development of ann optimized mucoadhesive buccal tablet containing flurbiprofen and lidocaine for dental pain. Acta Pharm. 2016;66(2):245–256. doi:10.1515/acph-2016-002027279067
   PubMed Web of Science ®Google Scholar
• MandaA, WalkerRB, KhamangaSM. An artificial neural network approach to predict the effects of formulation and process variables on prednisone release from a multipartite system. Pharmaceutics. 2019;11(3):109. doi:10.3390/pharmaceutics11030109
   PubMed Web of Science ®Google Scholar
• IbricS, JovanovicM, DjuricZ, et al. Artificial neural networks in the modeling and optimization of aspirin extended release tablets with Eudragit- l 100 as matrix substance. AAPS PharmSciTech. 2003;4(1):62–70. doi:10.1208/pt040109
   Google Scholar
• RehmanK, AminMC, MudaS. Influence of beta-cyclodextrin and chitosan in the formulation of a colon-specific drug delivery system. Drug Res. 2013;63:657–662. doi:10.1055/s-0033-1349129
   Google Scholar
• ElzeinT, Nasser-EddineM, DelaiteC, BistacS, DumasP. FTIR study of polycaprolactone chain organization at interfaces. J Colloid Interface Sci. 2004;273(2):381–387. doi:10.1016/j.jcis.2004.02.00115082371
   PubMed Web of Science ®Google Scholar
• MehtaR, ChawlaA, SharmaP, PawarP. Formulation and in vitro evaluation of Eudragit- s-100 coated naproxen matrix tablets for colon-targeted drug delivery system. JAPTR. 2013;4(1):31.23662280
   PubMedGoogle Scholar
• ChenS, ZhuJ, ChengJ. Preparation and in vitro evaluation of a novel combined multiparticulate delayed-onset sustained-release formulation of diltiazem hydrochloride. Pharmazie. 2007;62(12):907–913.18214341
   PubMed Web of Science ®Google Scholar
• Tugcu-DemirozF, AcarturkF, TakkaS, Konus-BoyunagaO. In-vitro and in-vivo evaluation of mesalazine–guar gum matrix tablets for colonic drug delivery. J Drug Target. 2004;12(2):105–112. doi:10.1080/1061186041000169375115203904
   PubMed Web of Science ®Google Scholar
• LachmanL, LiebermanHA, KanigJL. The Theory and Practice of Industrial Pharmacy. Lea & Febiger Philadelphia; 2010.
   Google Scholar
• HeemskerkJW, BeversEM, LindhoutT. Platelet activation and blood coagulation. Thromb Haemost. 2002;88(08):186–193. doi:10.1055/s-0037-161320912195687
   PubMed Web of Science ®Google Scholar
• JingJ, SunY. An αIIbβ3-and phosphatidylserine (PS)-binding recombinant fusion protein promotes ps-dependent anticoagulation and integrin-dependent antithrombosis. J Biol Chem. 2019;294(17):6670–6684. doi:10.1074/jbc.RA118.00604430803987
   PubMed Web of Science ®Google Scholar
• BharateSS, BharateSB, BajajAN. Interactions and incompatibilities of pharmaceutical excipients with active pharmaceutical ingredients: a comprehensive review. J Excip Food Chem. 2016;1(3):1131.
   Google Scholar
• JiminiM, KothariHA. Sustained release matrix type drug delivery system: a review. J Drug Deliv Ther. 2012;2(6).
   Google Scholar
• SchellekensRC, StuurmanFE, van der WeertFH, KosterinkJG, FrijlinkHW. A novel dissolution method relevant to intestinal release behaviour and its application in the evaluation of modified release mesalazine products. Eur J Pharm Sci. 2007;30(1):15–20. doi:10.1016/j.ejps.2006.09.00417085024
   PubMed Web of Science ®Google Scholar